TY - JOUR
T1 - Osteosarcoma in patients over 50 years of age
T2 - Multi-institutional retrospective analysis of 104 patients
AU - Nagano, Akihito
AU - Matsumoto, Seiichi
AU - Kawai, Akira
AU - Okuma, Tomotake
AU - Hiraga, Hiroaki
AU - Matsumoto, Yoshihiro
AU - Nishida, Yoshihiro
AU - Yonemoto, Tsukasa
AU - Hosaka, Masami
AU - Takahashi, Mitsuru
AU - Yoshikawa, Hideki
AU - Kunisada, Toshiyuki
AU - Asanuma, Kunihiro
AU - Naka, Norifumi
AU - Emori, Makoto
AU - Kubo, Tadahiko
AU - Kawashima, Hiroyuki
AU - Kawamoto, Teruya
AU - Yokoyama, Ryohei
AU - Tsukushi, Satoshi
AU - Sato, Kenji
AU - Okamoto, Takeshi
AU - Hiraoka, Koji
AU - Morioka, Hideo
AU - Tanaka, Kazuhiro
AU - Takagi, Tatsuya
AU - Iwamoto, Yukihide
AU - Ozaki, Toshifumi
PY - 2020/3
Y1 - 2020/3
N2 - Background: Primary osteosarcoma in elderly patients are rare malignant tumors. Its optimal treatment has not yet been determined. Methods: This retrospective study included 104 patients aged >50 years with resectable, non-metastatic osteosarcoma treated by the members of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group. The effects of adjuvant chemotherapy were estimated by comparing outcomes in patients who received surgery plus chemotherapy with those who underwent surgery alone. Results: Median age at presentation was 59 years. Neoadjuvant and adjuvant chemotherapy was administered to 83 (79.8%) patients. Patients who underwent surgery plus chemotherapy and those who underwent surgery alone had 5-year overall survival (OS) rates of 68.6% and 71.7%, respectively (p = 0.780), and 5-year relapse free survival (RFS) rates of 48.2% and 43.6%, respectively (p = 0.64). Univariate analysis showed that resection with wide margins was significantly correlated with better prognosis. Conclusions: The addition of chemotherapy to surgery did not improve OS or RFS in patients aged >50 years with resectable, non-metastatic osteosarcoma. Surgery with wide margins was only significantly prognostic of improved survival. The effect of chemotherapy in elderly osteosarcoma patients was unclear.
AB - Background: Primary osteosarcoma in elderly patients are rare malignant tumors. Its optimal treatment has not yet been determined. Methods: This retrospective study included 104 patients aged >50 years with resectable, non-metastatic osteosarcoma treated by the members of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group. The effects of adjuvant chemotherapy were estimated by comparing outcomes in patients who received surgery plus chemotherapy with those who underwent surgery alone. Results: Median age at presentation was 59 years. Neoadjuvant and adjuvant chemotherapy was administered to 83 (79.8%) patients. Patients who underwent surgery plus chemotherapy and those who underwent surgery alone had 5-year overall survival (OS) rates of 68.6% and 71.7%, respectively (p = 0.780), and 5-year relapse free survival (RFS) rates of 48.2% and 43.6%, respectively (p = 0.64). Univariate analysis showed that resection with wide margins was significantly correlated with better prognosis. Conclusions: The addition of chemotherapy to surgery did not improve OS or RFS in patients aged >50 years with resectable, non-metastatic osteosarcoma. Surgery with wide margins was only significantly prognostic of improved survival. The effect of chemotherapy in elderly osteosarcoma patients was unclear.
UR - http://www.scopus.com/inward/record.url?scp=85066286565&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85066286565&partnerID=8YFLogxK
U2 - 10.1016/j.jos.2019.04.008
DO - 10.1016/j.jos.2019.04.008
M3 - Article
C2 - 31155441
AN - SCOPUS:85066286565
VL - 25
SP - 319
EP - 323
JO - Journal of Orthopaedic Science
JF - Journal of Orthopaedic Science
SN - 0949-2658
IS - 2
ER -